🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🌟 Exciting findings reveals that intestinal low-dose irradiation (#ILDR) enhances the effects of immune checkpoint inhibitors #ICI or chemotherapy with off target #abscopal effect and intratumoural immune activation that is dependent on Gut composition #microbiome 🦠

Time for 🇨🇦 to Lead.

Hot out of the adaptive research oven!! Huge congrats to one of our rock star residents, Beatriz Guevara for her awesome work in IJROBP - The Red Journal for direct-to-unit/sim-free RT in highly complex treatment settings. Clinical trial opening soon by Lauren Henke, MD, MSCI Michael Yan, MD MPH !! RadOncUH

While widespread rediscovery and adoption of LDRT in America has always been "the goal": Never, EVER, did I think I'd live to see the day that a mainstream medicine platform like Peter Attia would open a show discussing radbio and LNT. LNT!! 10/10 from Dr. Mehta, love it.

Elisha Fredman MD Jeff Ryckman Peter Attia youtu.be/xtgQUiBuGVI?si…

📢 🚨#lungcancer peeps. Please consider Prof Andrea Bezjak from University of Toronto for your next IASLC president! A very deserving candidate and a great representative for #radonc!!! Laura Dawson #lcsm

What an honour to work with this outstanding #PROP team. Thank you Joanna Javor for your numerous patient cantered initiatives. We will miss Dr Cummings- mentor extraordinaire to us all and friend forever. Princess Margaret Cancer Centre Radiation Oncology

This trial may fit nicely in your portfolio, all ROs should consider opening it. Really broad eligibility criteria and will not conflict with oligomet studies. Im excited to get it going.

#ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rates (52% vs 30%) vs chemo alone in Phase III trial (N=124). First RCT evidence favoring NACRT in this tough-to-treat disease #radonc 🔗 meetings.asco.org/abstracts-pres…

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗 meetings.asco.org/abstracts-pres…

#ASCO2025 Another practice changing abstract for Gallbladder Cancer?! Phase 3 RCT in locally advanced gallbladder cancer not appropriate for R0 resection Neoadjuvant ChemoRT vs Chemo alone n = 124 (64 NACT, 60 NACRT) 🤩OS: 21.8 vs 10.1 mo (p = 0.006) ✅EFS: 10.6 vs 4.9 mo (p

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) Annals of Oncology doi.org/10.1016/j.anno… 👉ESMO-MCBS v2.0 changes scores of 13.6% of studies 👉adds toxicity annotations to 45.5% 🧐Important updates upon recognition of new needs and shortcomings ESMO - Eur. Oncology

Today we celebrate the retirement of a true giant in radiation oncology after 53 years. ❤️ Laura Dawson David Kirsch, MD, PhD

Matt Spraker Ours is this one!! Reena Engineer ascopubs.org/doi/10.1200/JC…

PANOVA-3: gem/abraxane +/- TTF in locally advanced pancreas cancer. #ASCO25 As compared to other approved LAPC therapies, numerical benefit to TTF is non-trivial (2 month OS, improvement in pain free interval 9 to 15 months), & cost/toxicity less than many. But… 1/3

Honored to share highlights of Reena Engineer’s presentation of POLCAGB phase III trial at #ASCO2025, a game changer for locally advanced gallbladder cancer Neoadj CRT vs CT alone: 🌟 Nearly doubled mOS (21.8 vs 10.1 months) 🌟 Significantly improved R0 resection (51.6% vs 29.7%)

Impressive trial showing impactful sustained benefit of exercise in early stage colon cancer. Congrats CCTG !

Congratulations to investigators CCTG for this remarkable trial, demonstrating the benefit of structured exercise for cancer survivors. Rebecca Wong Laura Dawson #ASCO25

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

x.com/i/article/1929…